Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inovio Pharmaceuticals : Reports Positive Data From Trial of COVID-19 Vaccine Candidate; Shares Rise Pre-Bell

05/10/2021 | 08:40am EDT


© MT Newswires 2021
All news about INOVIO PHARMACEUTICALS, INC.
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Un..
MT
09/01INOVIO PHARMACEUTICALS : to Present at Upcoming Investor Conferences in Septembe..
PR
08/26INOVIO PHARMACEUTICALS : Receives Authorization From Brazil Regulator to Start P..
MT
08/26INOVIO PHARMACEUTICALS : Receives Authorization to Conduct Phase 3 Efficacy Tria..
PR
08/26INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-..
CI
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next..
RE
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next..
RE
08/09INOVIO : Q2 Earnings Snapshot
AQ
08/09INOVIO PHARMACEUTICALS : Reports Narrower Q2 Loss on Higher Revenue
MT
08/09INOVIO PHARMACEUTICALS : Earnings Flash (INO) INOVIO PHARMACEUTICALS Posts Q2 Re..
MT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 4,71 M - -
Net income 2021 -272 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,26x
Yield 2021 -
Capitalization 1 712 M 1 712 M -
Capi. / Sales 2021 364x
Capi. / Sales 2022 17,3x
Nbr of Employees 262
Free-Float 98,3%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 8,14 $
Average target price 13,22 $
Spread / Average Target 62,4%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-8.02%1 712
MODERNA, INC.311.65%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.07%49 407
CELLTRION, INC.-23.26%31 021
SEAGEN INC.-10.81%27 940